BF Biosciences (BFBIO) Stock Overview
A biotech pharmaceutical company, manufactures, imports, and sells pharmaceutical products in Pakistan, Nepal, Afghanistan, Mauritania, Switzerland, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
BFBIO Community Fair Values
Create NarrativeSee what 12 others think this stock is worth. Follow their fair value or set your own to get alerts.
Top Community Narratives
BF Biosciences Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | PK₨138.49 |
| 52 Week High | PK₨189.97 |
| 52 Week Low | PK₨124.00 |
| Beta | 0 |
| 1 Month Change | -0.73% |
| 3 Month Change | -7.78% |
| 1 Year Change | -17.10% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 65.14% |
Recent News & Updates
Shareholder Returns
| BFBIO | PK Pharmaceuticals | PK Market | |
|---|---|---|---|
| 7D | -1.9% | -2.8% | -1.2% |
| 1Y | -17.1% | -2.7% | 24.1% |
Return vs Industry: BFBIO underperformed the PK Pharmaceuticals industry which returned -3% over the past year.
Return vs Market: BFBIO underperformed the PK Market which returned 23.8% over the past year.
Price Volatility
| BFBIO volatility | |
|---|---|
| BFBIO Average Weekly Movement | 4.8% |
| Pharmaceuticals Industry Average Movement | 4.9% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in PK Market | 9.5% |
| 10% least volatile stocks in PK Market | 3.1% |
Stable Share Price: BFBIO has not had significant price volatility in the past 3 months compared to the PK market.
Volatility Over Time: BFBIO's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 535 | Muhammad Rafiq | bfbio.com |
BF Biosciences Limited, a biotech pharmaceutical company, manufactures, imports, and sells pharmaceutical products in Pakistan, Nepal, Afghanistan, Mauritania, Switzerland, and internationally. The company offers pharmaceutical products for various therapeutic areas, including cardiometabolic disorders, cardiology, diabetes, anti-obesity, hepatology, gastroenterology, chronic kidney diseases, dermatology, antifungal treatments, antibiotics, antivirals, rheumatoid arthritis, nephrology, and oncology. It also provides injectables in vials, ampoules, and pre-filled syringes forms.
BF Biosciences Limited Fundamentals Summary
| BFBIO fundamental statistics | |
|---|---|
| Market cap | PK₨12.23b |
| Earnings (TTM) | PK₨591.76m |
| Revenue (TTM) | PK₨8.86b |
Is BFBIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BFBIO income statement (TTM) | |
|---|---|
| Revenue | PK₨8.86b |
| Cost of Revenue | PK₨5.12b |
| Gross Profit | PK₨3.74b |
| Other Expenses | PK₨3.15b |
| Earnings | PK₨591.76m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 6.70 |
| Gross Margin | 42.19% |
| Net Profit Margin | 6.68% |
| Debt/Equity Ratio | 33.6% |
How did BFBIO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/10 11:25 |
| End of Day Share Price | 2026/07/10 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BF Biosciences Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Azeem Akhundzada | Sherman Securities (Pvt.) Limited |